Are the drugs already on the shelf? Repurposing therapy for pancreatitis

The persistent absence of disease-modifying therapy for recurrent acute (RAP) and chronic pancreatitis (CP) represents one of the more conspicuous therapeutic gaps in gastroenterology.Despite substantial advances in delineating the molecular and cellular mechanisms that govern pancreatic injury-including disordered calcium signaling, mitochondrial dysfunction, immune activation, and fibrogenesis-clinical management remains largely anchored in supportive care rather than targeted pharmacologic intervention.For patients with recurrent acute pancreatitis, this therapeutic inertia carries durable consequences: recurrent inflammatory episodes herald progression to chronic pancreatitis with irreversible structural damage, lifelong metabolic and functional sequelae, pancreatic cancer risk, and poor quality of life.Against this backdrop, the repurposing of established drugs presents an intellectually and pragmatically attractive strategy, offering the possibility of accelerated translation through agents with biological plausibility and known safety profiles.That such approaches have yet to meaningfully alter clinical trajectories suggests that the central barrier to progress may lie less in pharmacology than in how pancreatitis is defined, phenotyped, and studied.The appeal of drug repurposing in pancreatitis is compelling.Several widely prescribed agents-including statins, protease inhibitors, antifibrotic or immunomodulatory agents (including non-prescription natural plant-derived compounds), and neuromodulating therapies-intersect with pathways implicated in pancreatic injury, repair, and neuroimmune nociceptive signaling.Their safety profiles are generally well established, their costs modest, and their availability immediate.The clinical studies of such agents have been notably inconsistent, with promising biological rationale giving way to neutral or inconclusive trial results.This pattern has been interpreted as evidence that pharmacologic intervention in pancreatitis is intrinsically futile.A more plausible interpretation, however, is that these failures reflect fundamental mismatches between drug mechanism, disease stage, patient phenotype, and trial design-limitations that repurposing alone cannot overcome, but that it may help expose.The therapeutic objectives of repurposed pharmacology in RAP and CP are threefold: alleviating pain, preventing recurrence, and slowing or stopping disease progression.